Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age "Scoped for Japanese"

Completed

Conditions: Small for Gestational Age (SGA)

Interventions: Drug: Somatropin

First Posted Date: 2013-07-12

Last Posted Date: 2023-09-25

Lead Sponsor: Pfizer

Target Recruit Count: 482

Registration Number: NCT01897766

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-05230907
Drug: Placebo for PF-05230907

First Posted Date: 2013-07-11

Last Posted Date: 2016-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 49

Registration Number: NCT01897142

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 2 x 15 mg/mL pegvisomant
Drug: 1 x 30 mg/mL pegvisomant

First Posted Date: 2013-07-09

Last Posted Date: 2013-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT01893866

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Phase 1

Completed

Conditions: Systemic Infections

Interventions: Drug: CAZ-AVI

First Posted Date: 2013-07-09

Last Posted Date: 2017-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT01893346

Locations: 🇺🇸
Research Site, Morgantown, West Virginia, United States

A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Carcinoma, Non Small Cell Lung
Ovarian Neoplasms
Neoplasms
Breast Neoplasms

Interventions: Drug: PF-06263507

First Posted Date: 2013-07-03

Last Posted Date: 2019-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT01891669

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer

Interventions: Drug: Enzalutamide

First Posted Date: 2013-06-28

Last Posted Date: 2024-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT01889238

Locations: 🇺🇸
Rocky Mountain Cancer Center Sky Ridge, Lone Tree, Colorado, United States
🇺🇸
Texas Oncology - Memorial City, Houston, Texas, United States
🇺🇸
Florida Cancer Specialist South Division, Fort Myers, Florida, United States

and more 67 locations

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

Phase 2

Completed

Conditions: Solid Tumor and Hematologic Malignancies

Interventions: Drug: MEK162

First Posted Date: 2013-06-24

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT01885195

Locations: 🇺🇸
Texas Oncology Austin Midtown, Dallas, Texas, United States
🇺🇸
Glacier View Research Institute - Cancer Oncology Dept, Kalispell, Montana, United States
🇺🇸
Texas Oncology Texas Oncology - Midland, Dallas, Texas, United States

and more 65 locations

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Other: Placebo
Drug: Tofacitinib

First Posted Date: 2013-06-20

Last Posted Date: 2017-09-15

Lead Sponsor: Pfizer

Target Recruit Count: 395

Registration Number: NCT01882439

Locations: 🇺🇸
St. Luke's Intermountain Research Center, Boise, Idaho, United States
🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

and more 122 locations

Use Of Fragmin In Hemodialysis

Phase 3

Completed

Conditions: Chronic Renal Failure

Interventions: Drug: Fragmin

First Posted Date: 2013-06-18

Last Posted Date: 2017-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 152

Registration Number: NCT01879618

Locations: 🇨🇦
Horizon Health Network/Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
Grey Nuns Community Hospital, Edmonton, Alberta, Canada
🇨🇦
Queen Elizabeth II Health Sciences Center (QEII) - VG Site, Halifax, Nova Scotia, Canada

and more 14 locations

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Tofacitinib 10 mg BID
Drug: Tofacitinib 5 mg BID
Drug: Adalimumab

First Posted Date: 2013-06-14

Last Posted Date: 2017-07-06

Lead Sponsor: Pfizer

Target Recruit Count: 422

Registration Number: NCT01877668

Locations: 🇫🇷
Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie, Corbeil Essonnes cedex, France
🇺🇸
Arthritis Center, Inc., Palm Harbor, Florida, United States
🇨🇿
Revmatologie s.r.o., Brno, Czechia

and more 120 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy